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 Efﬁ cient management of diabetic ketoacidosis (DKA) improves 
outcomes and reduces length of stay. While clinical audit 
improves the management of DKA, signiﬁ cant and sustained 
improvement is often difﬁ cult to achieve. We aimed to 
improve the management of DKA in our trust through the 
implementation of quality improvement methodology. Five 
speciﬁ c targets (primary drivers: ﬂ uid prescription, ﬁ xed rate 
intravenous insulin infusion, glucose measurement, ketone 
measurement and specialist referral) were selected following 
a baseline audit. Interventions (secondary drivers) were devel-
oped to improve these targets and included monthly feedback 
to departments of emergency medicine, acute medicine, and 
diabetes. Following our intervention, the mean average dura-
tion of DKA reduced from 22.0 hours to 10.2 hours. We demon-
strate that regular audit cycles with interventions introduced 
through the plan-do-study-act model is an effective way to 
improve the management of DKA. 
 KEYWORDS :  Causes ,  diabetic ketoacidosis ,  duration till resolution , 
 length of stay ,  quality improvement 
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 Regular and frequent feedback of speciﬁc clinical criteria 
delivers a sustained improvement in the management of 
diabetic ketoacidosis  
 Introduction 
 Diabetic ketoacidosis (DKA) is a complex metabolic 
derangement defined by the presence of hyperglycaemia 
(blood glucose>11 mmol/L), acidosis (pH<7.3 or 
bicarbonate<15 mmol/L) and ketonaemia (serum 
ketones>3 mmol/L). 1 The 2016 National Diabetes Inpatient 
Audit identified that 6.7% of inpatients have type 1 diabetes in 
England. 2 45.9% patients with type 1 diabetes were admitted 
with DKA in 2015. 2 Although overall mortality rates of patients 
who present with DKA have improved over time, recent studies 
have reported that DKA continues to be a major problem, 
especially among young adults. 3–6 
 The Joint British Diabetes Societies (JBDS) for Inpatient 
Care Group has produced guidance (2010, subsequently 
revised in 2013), standardising the management of DKA. 
This is supported by various professional organisations and 
patient groups (Diabetes UK, Association of British Clinical 
Diabetologists, British Society of Paediatric Endocrinology 
and Diabetes, Northern Irish Diabetologists, Society of Acute 
Medicine, Welsh Endocrine and Diabetes Society, and Scottish 
Diabetes Group), and guidelines for a good standard of care 
have been defined. 1 While audits against these guidelines have 
been conducted at our institution to assess the quality of care 
for DKA, a sustained improvement in care has been difficult 
to establish. Contributing factors to this difficulty may include 
complex audit cycles, accessibility of medical records and the 
transitory rotations of junior doctors. 
 Hypothesis and aims 
 We hypothesised that implementing a quality improvement 
methodology for a limited number of important clinical criteria 
and frequent feedback to front-line staff would improve the 
implementation and adherence to the JBDS guidelines for DKA 
management. Our aim was to reduce the total duration of DKA 
by 50% in a sustainable manner. In order to achieve this, we 
identified five factors for improvement (primary drivers). We 
identified another five areas of intervention (secondary drivers) 
to achieve the improvement in primary drivers. 
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 Methods 
 The study was undertaken at University Hospitals Birmingham 
NHS Foundation Trust – a large tertiary care foundation trust 
in the West Midlands, UK – from April 2014 to September 
2016. It is one of the largest hospitals in Western Europe with 
over 100,000 admissions per year. The study was divided into 
five distinct periods: pre-intervention (April 2014 to September 
2014), intervention (October 2014 to March 2015), early follow-
up (April 2015 to September 2015), intermediate follow-up 
(October 2015 to March 2015) and late follow-up (April 2016 to 
September 2016). All patients diagnosed with DKA according 
to national guidelines during the study period were included 
in the study. Patients managed in intensive care units were 
excluded from the study to avoid one-to-one care bias. Data 
was obtained with the help of informatics and electronic health 
records. The study was registered as a service improvement 
exercise with the trust’s clinical governance team and did not 
require formal ethical review. 
 We initially conducted an audit assessing DKA management 
by retrospective medical record analysis between April 2014 and 
September 2014. The results were presented to frontline staff 
involved in the management of DKA (emergency medicine, 
acute medicine and diabetes teams). Following discussion, five 
(primary drivers) were identified: 
 1  Fluid replacement 
Typically, patients with DKA are 100 mL/kg fl uid defi cient at 
the time of presentation. Fluid replacement is the most im-
portant initial management. Guidelines suggest at least four 
litres of fl uid replacement in the fi rst 12 hours (1,000 mL in 
the fi rst hour, 2,000 mL over the next four hours and a further 
2,000 mL over the next eight hours). 1 
 2  Fixed rate intravenous insulin infusion (FRIII) 
Insulin replacement will switch off lipolysis, the main driver 
of metabolic acidosis in DKA. 6 Guidelines recommend 
weight-based FRIII (calculated as 0.1 units/kg body weight) 
rather than the traditional variable rate insulin infusion in 
order to accommodate insulin-resistant states associated with 
obesity or pregnancy. 1 
 3  Glucose measurement 
Glucose falls sharply with insulin infusion; therefore, hourly 
glucose measurement is required. Supplementary glucose 
infusion may be required at the latter stages of DKA manage-
ment to provide substrate and avoid hypoglycaemia until 
ketone production is completely switched off. 
 4  Ketone measurement 
Guidelines recommend hourly ketone measurement to  assess 
the adequacy of insulin replacement and also assess for resolu-
tion. Further titration of insulin infusion to aim for a reduction 
in blood ketone levels by approximately 0.5 mmol/L/hour. 
 5  Specialist referral 
Patients with DKA should be referred to the diabetes  specialist 
team on admission to ensure necessary specialist input is 
provided at the earliest opportunity. 
 A 50% reduction in duration of DKA was considered the 
primary aim. We collected data for patient demographics, 
aetiology of the DKA and the aforementioned parameters 
during the first 12 hours following the diagnosis of DKA. 
 We adopted the plan-do-study-act (PDSA) method to address 
the primary outcome in this study. The PDSA cycle is a system 
where an idea is tested by trialling a change or intervention 
and assessing its impact (Box 1). 7,8 The various interventions 
(secondary drivers) introduced as part of our study are 
summarised in  Fig 1 : 
 1  Developing a real time audit tool 
Our fi rst intervention was to develop a real-time audit tool to 
minimise the delay between data collection and dissemination of 
results. We used existing electronic observation charts, prescrib-
ing and referral requests to capture these events. These enabled 
monitoring of the timings of glucose and ketone measurements, 
prescribing of fl uids and insulin, and specialist referral requests 
 2  Automatic referral to specialist team 
The electronic prescribing system was confi gured to generate an 
automatic referral to the diabetes team, triggered by FRIII pre-
scription. Although the latter duplicated most of the referrals 
from DKA admission, it ensured none of the DKA admissions 
were missed from specialist review. 
 3  Electronic surveillance of blood gas results 
Point-of-care blood gas analyser reports were not originally 
incorporated in our electronic observation. Surveillance was 
improved by incorporating them into the electronic system for 
clinical monitoring. This allowed the DKA to be electronically 
monitored, and the timing of resolution based on the pH, blood 
glucose and ketone measurement to be ascertained accurately. 
Nov 2014: introducon of 
automac electronic referral
of DKA to specialist team
and focus on improving
ﬂuid prescripon
Jan 2015: inclusion of
blood gas analysis in
trust's electronic
monitoring system
Dec 2014: focus on
improving FRIII and
hourly glucose and
ketone measurements
Oct 2014: QIP
iniated
Feb 2015:
introducing DKA
mnemonic
Mar 2015: revamping
DKA protocol
 Fig 1.  Timeline of interventions introduced during the study. DKA = 
diabetic ketoacidosis; FRIII = ﬁ xed rate intravenous insulin infusion; QIP = 
quality improvement project. 
 Box 1.  The plan-do-act-study cycle 
>  Plan – plan the test or observation, including a plan for 
collecting data
> Do – try out the test on a small scale
> Study – analyse the data and study the results
>  Act – refine the change, based on what was learned from the test.
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 4  Monthly feedback 
The results of monthly audits of the fi ve primary drivers were 
presented to the front-line teams –  departments of emergency 
medicine, acute medicine and diabetes via their clinical leads. 
 5  Education and redesigning the trust guideline 
Feedback from junior doctors suggested that the current 
hospital guideline for management of DKA was diffi cult to 
follow and had ‘too many words’. The guideline was therefore 
redesigned with an easy-to-remember mnemonic (Fig  2 ). The 
newly designed guideline was accessible through the trust’s 
intranet. Printed versions of the guidelines were posted in 
Management of 
DKA
A to K & D
I HAVE  
A     Airway
B     Breathing
C     Circulaon
D     Diabetes
E     Electrolytes and pH
F     Fluid replacement
G     Hourly Glucose
H     HbA1c
I     Fixed rate Insulin
J     Clinical Judgement
K     Hourly Ketones
D   Diabetes referral team
and
DIA B ETE
S
 Fig 2.  Mnemonic of the University Hospitals Birmingham NHS 
Foundation Trust’s guidelines for management of diabetic 
ketoacidosis. This was used to improve adherence to the guidelines. 
DKA = diabetic ketoacidosis; HbA1C = glycated haemoglobin. 
emergency medicine and acute medical units where most of 
the DKA patients are admitted. 
 Statistical analysis 
 The data were analysed using SPSS version 21 (IBM Corp) and 
Prism 6.0 (Graphpad Inc). DKA duration was log transformed 
for analysis to obtain a variable that is approximately normally 
distributed and presented in geometric means and associated 
95% confidence intervals (CI). The remaining data are presented 
as median ± interquartile range (IQR). Univariate analyses were 
performed using one-way analysis of variance, Kruskal-Wallis 
or Jonckheere-Terpstra tests for continuous and chi-square test 
or Kendall’s tau-b for categorical variables. The variation of 
the clinical criteria chosen for the study was measured as the 
deviation from the national guideline’s recommended value. 
 Results 
 A total of 259 episodes of DKA were included in the project. The 
baseline characteristics of the study population between the 
five groups are described in Table  1 . There was no statistically 
significant difference in age distribution between the five groups. 
Poor compliance with treatment for diabetes and inter-current 
illness were the most common causes of DKA in our study. The 
total duration of DKA was reduced significantly following our 
intervention (p<0.001) (Fig  3 ). DKA duration (geometric mean 
and 95% CI) in the five groups were 22.0 (17.7–27.5) hours, 18.3 
(15.2–22.0) hours, 12.0 (9.8–14.8) hours, 7.4 (6.4–8.7) hours and 
10.2 (8.2–12.7) hours, respectively. However, we did not notice a 
significant difference in the length of stay. The respective lengths 
of stay in the five groups were 75 (28–223) hours, 69 (41–179) 
hours, 87 (44–190), 71 (42–328) hours and 75 (48–149) hours. 
There was a significant reduction in the dispersion of values for 
FRIII. There was an increased proportion of values within 20% 
of the guideline value (67% at pre-intervention to 92% in the 
late follow-up period (p=0.002)). A similar trend was noted for 
hourly glucose measurements (the proportion of patients within 
20% variation of the guideline increased from 33% to 47%); 
however, this was not statistically significant (p=0.06). There 
was no significant change in the variation of fluid prescription 
and ketone measurements (Fig  4 ). All patients were referred to 
the diabetes team upon the diagnosis of DKA during the post-
intervention period. 
 Discussion 
 In this study, we show that auditing DKA management against 
five simple criteria and feeding the results back to front-line 
staff, along with systems enhancement for early identification 
and monitoring by a specialist team, reduces DKA duration 
in a sustained manner. We attribute this to a PDSA model of 
quality improvement. 
 The usual pattern of DKA management at our trust involves 
admission into the acute medical unit, through the emergency 
department, where they are managed until resolution. The 
patients’ glucose and ketones are monitored hourly and 
necessary changes in insulin infusion and fluid replacement 
are made as per the trust’s guidelines. Following resolution, 
patients are either discharged from the acute medical unit, 
if they have already been reviewed by the diabetes team, 
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or transferred to a general medical ward where they await 
further review from the diabetes team and a safe discharge. 
The average healthcare cost in our acute medical unit is 
£14.1 per hour. Therefore, assuming a pragmatic model where 
healthcare delivery remained the same throughout the study, 
DKA management from diagnosis to resolution in the acute 
medical unit cost £22,338.50 at the beginning of the study. This 
reduced to £6,489.50 at the end of the study. However, length of 
stay was not significantly reduced. This is likely due to factors 
that influence discharge after resolution of DKA (for example 
patient education, review of home support, dispensing of take 
home therapies). While the calculated savings are therefore 
hypothetical, the quicker resolution helps free up acute medical 
beds for other ill patients. 
 Delivering improvements in quality and patient safety 
remains a priority for the NHS. However, current methods 
lack a coherent, sustained and nationally replicable model. 9 
There is a need for multifaceted approaches that are iteratively 
able to adapt to local context and unforeseen difficulties. 10 
Furthermore, the NHS must effectively utilise ‘organisational 
learning’ skills through quality improvement to effectively 
sustain improvements in an ever changing healthcare system. 11 
 We have demonstrated that the PDSA model of quality 
improvement, based around repeated assessment and 
intervention cycles, is an effective way to improve DKA 
management. Porter  et al were able to demonstrate a significant 
and sustained improvement in diabetes management in their 
primary care in Western Australia by adopting the PDSA 
model. 12 The model encourages organisational learning and 
communication through the development of dissemination 
methods. In comparison, a simple clinical audit may not have 
the required number of interventions and/or assessments to 
sustain improvement. 
 Limitations 
 Complications such as hypokalaemia and hypoglycaemia 
are associated with DKA management. 13,14 These were not 
measured in this study and we were therefore unable to assess 
whether our intervention affected this outcome. We did not 
assess whether the shorter duration of DKA following the 
intervention affected DKA readmission rates. While DKA 
patients managed in the intensive care unit were excluded in the 
current study, we believe it was correct to do so. A recent survey 
of DKA management in the intensive care setting across East of 
England showed that majority of the centres do not follow JBDS 
guidelines. 15 Also, these patients are managed with one-to-one 
nursing care with continuous monitoring, which may result in 
one-to-one care bias. Their inclusion would have skewed the 
results when compared with patients managed elsewhere with 
standard care. 
 Table 1.  Age, gender, aetiology and rates of new onset diabetes and specialist referral 
Group Pre-intervention 
(n=52) 
Intervention 
(n=52) 
Post-intervention 
(n=55) 
Intermediate 
follow-up (n=64) 
Late follow-up 
(n=36) 
Median age, years (IQR) 28 (20–51) 38 (23–47) 32 (21–56) 32 (20–62) 29 (20–49)
Male gender, n(%) 22 (42.3) 33 (63.5) 30 (54.5) 26 (40.6) 10 (27.8)
 Aetiology, n(%) 
Alcohol-related 1 (1.9) 5 (9.6) 2 (3.6) 1 (1.6) 2 (5.6)
Inter-current illness 9 (17.3) 19 (36.5) 11 (20.0) 12 (18.8) 12 (33.3)
Poor compliance 14 (26.9) 14 (26.9) 29 (52.7) 18 (28.1) 8 (22.2)
Sepsis 6 (11.5) 2 (3.8) 2 (3.6) 9 (14.1) 3 (8.3)
Surgical 8 (15.4) 5 (9.6) 2 (3.6) 7 (10.9) 0
New diagnosis of type 1 diabetes 7 (13.5) 2 (3.8) 6 (10.9) 4 (6.3) 2 (5.6)
Unclear 7 (13.5) 5 (9.6) 3 (5.5) 13 (20.3) 9 (25.0)
Referral to diabetes team 48 (92.3) 37 (71.2) 55 (100) 64 (100) 36 (100)
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 Fig 3.  Diabetic ketoacidosis duration during ﬁ ve distinct periods . The 
geometric means (95% CI) were 22.0 (17.7–27.5) hours pre-intervention, 
18.3 (15.2–22.0) hours during intervention, 12.0 (9.8–14.8) hours at early 
follow-up, 7.4 (6.4–8.7) hours at intermediate follow-up and 10.2 (8.2–12.7) 
hours at late follow-up. The total duration of diabetic ketoacidosis was 
reduced signiﬁ cantly following our intervention (p<0.001). 
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 Conclusions 
 In our study, we were able to demonstrate a significant and 
sustained reduction in DKA. We attribute this to the PDSA 
model of quality improvement where we identified the 
primary drivers for change and developed secondary driver 
interventions to achieve the improvements. We propose that the 
primary drivers for improvement in resolution time of DKA be 
tested in other trusts to confirm reproducibility. ■ 
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 Fig 4.  Deviation from guidance for four primary drivers for diabetic ketoacidosis management . A – ﬁ xed rate intravenous insulin infusion; B – ﬂ uids; C 
– hourly glucose measurement; D – hourly ketone measurement. There was an increased proportion of values for ﬁ xed rate intravenous insulin infusion within 
the 20% of guideline value following our interventions during the study (67% at pre-intervention to 92% in the late follow-up period (p=0.002)). A similar 
trend was noted for hourly glucose measurements (the proportion of patients within 20% variation of the guideline increased from 33% to 47%); however, 
this was not statistically signiﬁ cant (p=0.06). There was no signiﬁ cant change in the variation of ﬂ uid prescription and ketone measurements. 
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